CVS Health Corporation $CVS Stock Position Lessened by Pzena Investment Management LLC

Pzena Investment Management LLC trimmed its holdings in shares of CVS Health Corporation (NYSE:CVS) by 11.6% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 13,773,053 shares of the pharmacy operator’s stock after selling 1,808,254 shares during the period. CVS Health comprises approximately 3.2% of Pzena Investment Management LLC’s holdings, making the stock its 7th biggest holding. Pzena Investment Management LLC’s holdings in CVS Health were worth $989,181,000 as of its most recent SEC filing.

Several other institutional investors have also recently modified their holdings of CVS. Caitong International Asset Management Co. Ltd increased its position in CVS Health by 407.2% during the third quarter. Caitong International Asset Management Co. Ltd now owns 350 shares of the pharmacy operator’s stock worth $26,000 after buying an additional 281 shares in the last quarter. Swiss RE Ltd. purchased a new stake in shares of CVS Health in the fourth quarter valued at $26,000. Sankala Group LLC acquired a new stake in shares of CVS Health during the fourth quarter valued at $28,000. Global Trust Asset Management LLC increased its position in CVS Health by 344.8% during the 1st quarter. Global Trust Asset Management LLC now owns 387 shares of the pharmacy operator’s stock worth $28,000 after purchasing an additional 300 shares in the last quarter. Finally, Mcguire Capital Advisors Inc. acquired a new position in CVS Health in the 4th quarter valued at about $28,000. 80.66% of the stock is currently owned by institutional investors and hedge funds.

More CVS Health News

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: Analysts highlighted CVS Health’s strong earnings surprise track record and said the company appears positioned to beat estimates again in its next quarterly report, which supports sentiment around future profits. Will CVS Health (CVS) Beat Estimates Again in Its Next Earnings Report?
• Positive Sentiment: CVS was also featured in a CNBC report about Medicare beginning to cover obesity drugs, with CVS and Walmart helping seniors navigate the new coverage landscape, underscoring CVS’s role in a growing healthcare service area. Healthy Returns: Walmart, CVS step in to help seniors navigate Medicare coverage of obesity drugs
• Positive Sentiment: CVS Health also published consumer-health content on women’s health and preventive screenings, reinforcing its push to drive pharmacy, clinic, and health-services engagement. CVS Health: A Menopause Revolution Is Long Overdue
• Positive Sentiment: An executive from CVS Health was named to Choice Hotels’ board, which is a small signal of leadership visibility and management credibility. Choice Hotels International Appoints Artificial Intelligence Leader Ali Keshavarz to Board of Directors
• Neutral Sentiment: A healthcare-advice article said UnitedHealth, Humana, and CVS denied post-hospital care at some of the highest rates, which could keep attention on utilization management and prior-authorization practices, but the piece does not provide a direct financial update. UnitedHealth, Humana, CVS Denied Post-Hospital Care At Some Of The Highest Rates
• Neutral Sentiment: CVS also appeared in coverage of its support for America250, which is mainly a branding/community-relations item and likely has limited near-term stock impact. CVS Health Exec Explains Why Its Support of America250 is ‘Natural Fit’

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on CVS shares. Wells Fargo & Company upped their target price on shares of CVS Health from $102.00 to $103.00 and gave the company an “overweight” rating in a report on Friday, May 8th. Bank of America boosted their price objective on shares of CVS Health from $100.00 to $110.00 and gave the company a “buy” rating in a research report on Monday, June 22nd. Sanford C. Bernstein upped their price objective on shares of CVS Health from $94.00 to $106.00 and gave the company an “outperform” rating in a research note on Tuesday, May 12th. Barclays lifted their target price on shares of CVS Health from $101.00 to $106.00 and gave the stock an “overweight” rating in a research note on Tuesday, May 26th. Finally, HSBC boosted their price target on CVS Health from $83.00 to $85.00 and gave the company a “hold” rating in a report on Tuesday, May 5th. Twenty-one analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $101.28.

Insider Buying and Selling at CVS Health

In related news, EVP Tilak Mandadi sold 69,551 shares of CVS Health stock in a transaction on Friday, May 8th. The stock was sold at an average price of $89.58, for a total value of $6,230,378.58. Following the transaction, the executive vice president owned 10,133 shares in the company, valued at approximately $907,714.14. This trade represents a 87.28% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Larry Robbins sold 370,462 shares of the business’s stock in a transaction dated Thursday, May 21st. The shares were sold at an average price of $93.45, for a total value of $34,619,673.90. Following the sale, the director directly owned 4,824,799 shares of the company’s stock, valued at approximately $450,877,466.55. This trade represents a 7.13% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 3,441,551 shares of company stock valued at $323,703,977 over the last three months. Corporate insiders own 0.85% of the company’s stock.

CVS Health Trading Up 1.3%

NYSE CVS opened at $104.83 on Thursday. The company has a market cap of $133.75 billion, a P/E ratio of 46.18, a P/E/G ratio of 1.01 and a beta of 0.60. CVS Health Corporation has a 12 month low of $58.50 and a 12 month high of $106.15. The company has a debt-to-equity ratio of 0.78, a current ratio of 0.87 and a quick ratio of 0.66. The company has a 50-day moving average of $93.44 and a 200-day moving average of $82.96.

CVS Health (NYSE:CVS) last released its earnings results on Wednesday, May 6th. The pharmacy operator reported $2.57 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.21 by $0.36. CVS Health had a net margin of 0.72% and a return on equity of 11.88%. The firm had revenue of $100.43 billion during the quarter, compared to the consensus estimate of $94.99 billion. During the same period in the previous year, the firm earned $2.25 earnings per share. CVS Health’s revenue was up 6.2% compared to the same quarter last year. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. As a group, equities analysts predict that CVS Health Corporation will post 7.44 earnings per share for the current year.

CVS Health Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over?the?counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in?store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk?in medical clinics and HealthHUB locations that offer expanded clinical services.